Recent progress in TGF-β inhibitors for cancer therapy

Cheng Yi Huang; Chih Ling Chung; Tsung Hui Hu; Jih Jung Chen; Pei Feng Liu; Chun Lin Chen

doi:10.1016/j.biopha.2020.111046

Recent progress in TGF-β inhibitors for cancer therapy

Cheng Yi Huang, Chih Ling Chung, Tsung Hui Hu, Jih Jung Chen, Pei Feng Liu, Chun Lin Chen^*

^*此作品的通信作者

藥學系

研究成果: Review article › 同行評審

110 引文斯高帕斯（Scopus）

摘要

Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.

原文	English
文章編號	111046
期刊	Biomedicine and Pharmacotherapy
卷	134
DOIs	https://doi.org/10.1016/j.biopha.2020.111046
出版狀態	Published - 2月 2021

UN SDG

此研究成果有助於以下永續發展目標

存取文件

10.1016/j.biopha.2020.111046

其它文件與鏈接

Link to publication in Scopus

引用此

@article{aaf9e9345efc4f338572b6db54f350c8,

title = "Recent progress in TGF-β inhibitors for cancer therapy",

abstract = "Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.",

keywords = "Cancer therapy, Endocytosis, Lipid raft, Small-molecule inhibitor, TGF-β inhibitor",

author = "Huang, {Cheng Yi} and Chung, {Chih Ling} and Hu, {Tsung Hui} and Chen, {Jih Jung} and Liu, {Pei Feng} and Chen, {Chun Lin}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2021",

month = feb,

doi = "10.1016/j.biopha.2020.111046",

language = "English",

volume = "134",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

}

TY - JOUR

T1 - Recent progress in TGF-β inhibitors for cancer therapy

AU - Huang, Cheng Yi

AU - Chung, Chih Ling

AU - Hu, Tsung Hui

AU - Chen, Jih Jung

AU - Liu, Pei Feng

AU - Chen, Chun Lin

PY - 2021/2

Y1 - 2021/2

N2 - Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.

AB - Transforming growth factor-β (TGF-β) is a multifunctional cytokine that is involved in proliferation, metastasis, and many other important processes in malignancy. Inhibitors targeting TGF-β have been considered by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now. Unfortunately, several of these programs have recently been relinquished, and most companies that remain in the contest are progressing slowly and cautiously. This review summarizes the TGF-β signal transduction pathway, its roles in oncogenesis and fibrotic diseases, and advancements in antibodies and small-molecule inhibitors of TGF-β.

KW - Cancer therapy

KW - Endocytosis

KW - Lipid raft

KW - Small-molecule inhibitor

KW - TGF-β inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85098467921&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2020.111046

DO - 10.1016/j.biopha.2020.111046

M3 - Review article

C2 - 33341049

AN - SCOPUS:85098467921

SN - 0753-3322

VL - 134

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

M1 - 111046

ER -

Recent progress in TGF-β inhibitors for cancer therapy

摘要

UN SDG

存取文件

其它文件與鏈接

指紋

引用此